Can-Fite Biopharma Ltd ADR (CANF)

$4.05 -0.15 (-3.57%)
Market Cap 5.50M
Revenue (ttm) 670,000.00
Net Income (ttm) -7.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,176.12%
Debt to Equity Ratio 0.00
Volume 64,000
Avg Vol 879,876
Day's Range N/A - N/A
Shares Out 1.31M
Stochastic %K 2%
Beta 1.01
Analysts Sell
Price Target $70.00

Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic c...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 924 1114
Fax: 972 3 924 9378
Address:
26 Ben Gurion Street, Ramat Gan, Israel
GeeJoon
GeeJoon Mar. 10 at 12:35 AM
$CANF in this vc 2 years ago, Motti expected it would take 2 to 4 years to commercialise their drug, so now it is remaining 2 years, namodenoson is more likely to be their first product in market, orphan drug, no competitors https://youtu.be/VEikAf3k5QA?si=_AFDoAAmvzvjJb5G
0 · Reply
GeeJoon
GeeJoon Mar. 10 at 12:04 AM
$CANF psorasis p3 interim result in q2 will rocket sp 10x, buy now when its low
1 · Reply
Pindis7
Pindis7 Mar. 10 at 12:01 AM
$CANF glad I took my loss. It wasn’t big but shouldn’t have lost anything on this company.
0 · Reply
GeeJoon
GeeJoon Mar. 9 at 8:38 PM
$CANF CEO Pnina Fishman‏ already looked like a zombie...how a woman like that can lead a company to success...she even not own a single share https://www.youtube.com/watch?v=sek4HE0VOyg
0 · Reply
Peaceouty
Peaceouty Mar. 9 at 7:56 PM
$CANF Freaking moron Sabby Management got this a SSR for tomorrow.
0 · Reply
Patrick_Squarepants
Patrick_Squarepants Mar. 9 at 6:05 PM
$CANF Ending up below the price right before the PR
1 · Reply
GeeJoon
GeeJoon Mar. 9 at 2:34 PM
$CANF H.C. Wainwright: wtf, who would buy those $5 shares from me
1 · Reply
Rvazstocksfl
Rvazstocksfl Mar. 9 at 2:29 PM
$CANF told ya
0 · Reply
GeeJoon
GeeJoon Mar. 9 at 2:15 PM
$CANF 346m turnover on 4 Mar, no big fish inside?
0 · Reply
GeeJoon
GeeJoon Mar. 9 at 2:02 PM
$CANF 5m market cap, still no one buy it
0 · Reply
Latest News on CANF
Can-Fite's Namodenoson Hits Phase 2a Goal; Raises $4M Via Warrants

2026-03-04T16:50:16.000Z - 7 days ago

Can-Fite's Namodenoson Hits Phase 2a Goal; Raises $4M Via Warrants

Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study

Wed, 04 Mar 2026 10:07:28 -0500 - 7 days ago

Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study

Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study

2026-03-04T15:07:28.000Z - 7 days ago

Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study

Can-Fite BioPharma (CANF) Achieves Positive Results in Pancreatic Cancer Study

2026-03-04T12:34:33.000Z - 7 days ago

Can-Fite BioPharma (CANF) Achieves Positive Results in Pancreatic Cancer Study

Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study

Wed, 04 Mar 2026 07:00:00 -0500 - 7 days ago

Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study

Can-Fite BioPharma (CANF) Unveils Promising Obesity Study Results

2026-02-17T12:36:34.000Z - 22 days ago

Can-Fite BioPharma (CANF) Unveils Promising Obesity Study Results

Can-Fite (CANF) Gains Canadian Patent for Anti-Obesity Drug Namodenoson

2026-02-09T12:30:05.000Z - 4 weeks ago

Can-Fite (CANF) Gains Canadian Patent for Anti-Obesity Drug Namodenoson

Can-Fite BioPharma (CANF) Treatment Aids Successful Liver Transplant

2026-02-05T12:33:49.000Z - 4 weeks ago

Can-Fite BioPharma (CANF) Treatment Aids Successful Liver Transplant

Can-Fite BioPharma (CANF) Completes Patient Enrollment in Pancreatic Cancer Trial

2026-01-20T12:37:35.000Z - 7 weeks ago

Can-Fite BioPharma (CANF) Completes Patient Enrollment in Pancreatic Cancer Trial

Can-Fite BioPharma (CANF) Announces 1-for-3,000 Reverse Stock Split

2025-12-23T22:55:20.000Z - 2 months ago

Can-Fite BioPharma (CANF) Announces 1-for-3,000 Reverse Stock Split

Can-Fite BioPharma (CANF) Announces Significant Reverse Split

2025-12-23T22:25:23.000Z - 2 months ago

Can-Fite BioPharma (CANF) Announces Significant Reverse Split

Can-Fite BioPharma approves 1-for-3,000 reverse share split; shares down

2025-12-23T21:52:00.000Z - 2 months ago

Can-Fite BioPharma approves 1-for-3,000 reverse share split; shares down

Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change

Tue, 23 Dec 2025 16:46:00 -0500 - 2 months ago

Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change

CANF: D. Boral Capital Lowers Price Target But Maintains Buy Rating | CANF Stock News

2025-12-17T13:30:15.000Z - 3 months ago

CANF: D. Boral Capital Lowers Price Target But Maintains Buy Rating | CANF Stock News

CANF: Can-Fite BioPharma Advances Clinical Trials and Strengthens Financial Position

2025-12-16T15:29:50.000Z - 3 months ago

CANF: Can-Fite BioPharma Advances Clinical Trials and Strengthens Financial Position

Can-Fite Provides Update on Clinical and Financial Status

Tue, 16 Dec 2025 09:19:00 -0500 - 3 months ago

Can-Fite Provides Update on Clinical and Financial Status

Can-Fite BioPharma (CANF) to Engage in Strategic Collaborations at BioFIT 2025

2025-11-24T12:30:24.000Z - 3 months ago

Can-Fite BioPharma (CANF) to Engage in Strategic Collaborations at BioFIT 2025

Can-Fite BioPharma (CANF) Secures Patent Approval in Brazil for Erectile Dysfunction Treatment

2025-11-20T12:42:31.000Z - 3 months ago

Can-Fite BioPharma (CANF) Secures Patent Approval in Brazil for Erectile Dysfunction Treatment

Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil

Thu, 20 Nov 2025 07:00:00 -0500 - 3 months ago

Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil

CANF: Analyst Jason Kolbert Maintains Buy Rating and Price Target | CANF Stock News

2025-11-18T20:00:37.000Z - 4 months ago

CANF: Analyst Jason Kolbert Maintains Buy Rating and Price Target | CANF Stock News

Can-Fite BioPharma's (CANF) Namodenoson Shows Promising Long-Term Survival

2025-11-18T12:30:20.000Z - 4 months ago

Can-Fite BioPharma's (CANF) Namodenoson Shows Promising Long-Term Survival

CANF: HC Wainwright Initiates Buy Rating with $2.50 Price Target | CANF Stock News

2025-11-04T12:01:46.000Z - 4 months ago

CANF: HC Wainwright Initiates Buy Rating with $2.50 Price Target | CANF Stock News

CANF: Analyst Jason Kolbert Maintains Buy Rating and $11 PT | CANF Stock News

2025-09-16T12:32:06.000Z - 6 months ago

CANF: Analyst Jason Kolbert Maintains Buy Rating and $11 PT | CANF Stock News

Can-Fite BioPharma (CANF) Reports Breakthrough in Liver Cirrhosis Treatment

2025-09-15T12:40:09.000Z - 6 months ago

Can-Fite BioPharma (CANF) Reports Breakthrough in Liver Cirrhosis Treatment

Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.2M

2025-08-29T06:23:58.000Z - 6 months ago

Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.2M

Can-Fite Reports H1 2025 Financial Results and Clinical Update

Thu, 28 Aug 2025 08:47:00 -0400 - 6 months ago

Can-Fite Reports H1 2025 Financial Results and Clinical Update

Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

Wed, 30 Jul 2025 07:04:00 -0400 - 8 months ago

Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

Can-Fite Announces Up To $15.0 Million Public Offering

Mon, 28 Jul 2025 12:24:00 -0400 - 8 months ago

Can-Fite Announces Up To $15.0 Million Public Offering

Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia

Mon, 28 Jul 2025 07:00:00 -0400 - 8 months ago

Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia

Can-Fite BioPharma launches best-efforts offering of ADSs and warrants

2025-07-23T21:41:13.000Z - 8 months ago

Can-Fite BioPharma launches best-efforts offering of ADSs and warrants

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Thu, 17 Apr 2025 08:55:00 -0400 - 11 months ago

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Mon, 14 Apr 2025 14:28:00 -0400 - 11 months ago

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.67M

2025-04-14T12:35:35.000Z - 11 months ago

Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.67M

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Thu, 20 Mar 2025 09:45:00 -0400 - 1 year ago

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Wed, 19 Mar 2025 09:00:00 -0400 - 1 year ago

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Mon, 03 Mar 2025 06:00:00 -0500 - 1 year ago

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25

Mon, 10 Feb 2025 07:10:00 -0500 - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Wed, 05 Feb 2025 07:00:00 -0500 - 1 year ago

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson

Mon, 30 Dec 2024 07:00:00 -0500 - 1 year ago

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Fri, 22 Nov 2024 09:00:00 -0500 - 1 year ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Mon, 11 Nov 2024 07:00:00 -0500 - 1 year ago

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Mon, 04 Nov 2024 07:08:00 -0500 - 1 year ago

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

Fri, 18 Oct 2024 09:06:00 -0400 - 1 year ago

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

Can-Fite stock rallies 17% on FDA orphan drug designation

2024-10-09T19:22:45.000Z - 1 year ago

Can-Fite stock rallies 17% on FDA orphan drug designation

FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer

Wed, 09 Oct 2024 07:00:00 -0400 - 1 year ago

FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Mon, 16 Sep 2024 07:00:00 -0400 - 1 year ago

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Can-Fite BioPharma files to sell 1.77B shares of common stock for holders

2024-08-30T21:12:05.000Z - 1 year ago

Can-Fite BioPharma files to sell 1.77B shares of common stock for holders

Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.32M

2024-08-29T16:37:04.000Z - 1 year ago

Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.32M

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Thu, 29 Aug 2024 08:15:00 -0400 - 1 year ago

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Fri, 09 Aug 2024 09:00:00 -0400 - 1 year ago

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

Aug 8, 2024, 7:01 PM EDT - 1 year ago

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

Can-Fite Provides Namodenoson Patent Update

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Provides Namodenoson Patent Update

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8

Jul 17, 2024, 7:00 AM EDT - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix

Jun 28, 2024, 7:00 AM EDT - 1 year ago

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Jun 10, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

May 29, 2024, 7:00 AM EDT - 1 year ago

Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

May 27, 2024, 7:00 AM EDT - 1 year ago

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6

May 23, 2024, 7:00 AM EDT - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

May 13, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

May 10, 2024, 9:00 AM EDT - 1 year ago

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NTRB

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

May 9, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

May 6, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Apr 25, 2024, 7:00 AM EDT - 2 years ago

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Apr 15, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Apr 3, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

Can-Fite Reports 2023 Financial Results and Clinical Update

Mar 28, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Reports 2023 Financial Results and Clinical Update

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Mar 11, 2024, 7:00 AM EDT - 2 years ago

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

Feb 28, 2024, 7:00 AM EST - 2 years ago

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

Jan 30, 2024, 7:00 AM EST - 2 years ago

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study

Jan 29, 2024, 7:00 AM EST - 2 years ago

Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study

The Anti-Obesity Effect of Can-Fite's Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies

Dec 20, 2023, 7:00 AM EST - 2 years ago

The Anti-Obesity Effect of Can-Fite's Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies

GeeJoon
GeeJoon Mar. 10 at 12:35 AM
$CANF in this vc 2 years ago, Motti expected it would take 2 to 4 years to commercialise their drug, so now it is remaining 2 years, namodenoson is more likely to be their first product in market, orphan drug, no competitors https://youtu.be/VEikAf3k5QA?si=_AFDoAAmvzvjJb5G
0 · Reply
GeeJoon
GeeJoon Mar. 10 at 12:04 AM
$CANF psorasis p3 interim result in q2 will rocket sp 10x, buy now when its low
1 · Reply
Pindis7
Pindis7 Mar. 10 at 12:01 AM
$CANF glad I took my loss. It wasn’t big but shouldn’t have lost anything on this company.
0 · Reply
GeeJoon
GeeJoon Mar. 9 at 8:38 PM
$CANF CEO Pnina Fishman‏ already looked like a zombie...how a woman like that can lead a company to success...she even not own a single share https://www.youtube.com/watch?v=sek4HE0VOyg
0 · Reply
Peaceouty
Peaceouty Mar. 9 at 7:56 PM
$CANF Freaking moron Sabby Management got this a SSR for tomorrow.
0 · Reply
Patrick_Squarepants
Patrick_Squarepants Mar. 9 at 6:05 PM
$CANF Ending up below the price right before the PR
1 · Reply
GeeJoon
GeeJoon Mar. 9 at 2:34 PM
$CANF H.C. Wainwright: wtf, who would buy those $5 shares from me
1 · Reply
Rvazstocksfl
Rvazstocksfl Mar. 9 at 2:29 PM
$CANF told ya
0 · Reply
GeeJoon
GeeJoon Mar. 9 at 2:15 PM
$CANF 346m turnover on 4 Mar, no big fish inside?
0 · Reply
GeeJoon
GeeJoon Mar. 9 at 2:02 PM
$CANF 5m market cap, still no one buy it
0 · Reply
Eli18222
Eli18222 Mar. 9 at 10:37 AM
$CANF on or off💥💢
0 · Reply
GeeJoon
GeeJoon Mar. 7 at 2:34 PM
$CANF any hints? "Secondary endpoints included overall survival (OS) and progression-free survival (PFS). Survival follow-up remains ongoing, with 1/3 of patients currently alive at the time of data cut-off. As follow-up continues, survival outcomes are expected to further mature and will be announced during upcoming scientific meetings."
1 · Reply
GeeJoon
GeeJoon Mar. 7 at 12:19 PM
$CANF let's do a math, 1.3m outstanding shares, 0.8m new issued from executed warrants, if good data out in 2026, CANF is very likely to execute the remaining 1.6m warrants, their plan might be selling cheap shares to some jewish big fish and let those strong hand to pump up the stock, insider will be holding 64% of the company!
1 · Reply
GeeJoon
GeeJoon Mar. 7 at 10:02 AM
$CANF miracle in 2026? - psoriasis P3 interim result in Q2 - pancreatic cancer P2b result in Q3 - liver cancer HCC CP7 P3 interim result in Q4
0 · Reply
GeeJoon
GeeJoon Mar. 7 at 8:33 AM
$CANF guess who would hold that 30% new shares?
0 · Reply
GeeJoon
GeeJoon Mar. 7 at 6:41 AM
$CANF P2a result earlier than expectation, hope P2b and Psoriasis P3 interim result out sooner "Namodenoson is being evaluated in a Phase IIa clinical study in patients with pancreatic cancer who have failed first-line treatment. Patient enrollment in this study is nearing completion, and the Company expects to report data during the second quarter of 2026."
0 · Reply
Peaceouty
Peaceouty Mar. 6 at 10:56 PM
$CANF insider ownership is 0.01%
0 · Reply
Peaceouty
Peaceouty Mar. 6 at 10:54 PM
$CANF Management doesn’t buy.. we don’t buy. Let it go to hell.
0 · Reply
Peaceouty
Peaceouty Mar. 6 at 10:08 PM
$CANF Now there’s a major HF shorting (Sabby), because of weak management. Wouldn’t be surprised if there’s bribes..
0 · Reply
Patrick_Squarepants
Patrick_Squarepants Mar. 6 at 9:10 PM
$CANF They didn't even do a press release on the closing of the offering?
1 · Reply
MarTho_35
MarTho_35 Mar. 6 at 8:42 PM
$CANF microcap biotech moving under the radar if volume ignition shows up squeeze risk grows
0 · Reply
Farhas80
Farhas80 Mar. 6 at 7:49 PM
$NLST $CANF I am really surprised earning and Cfec oral had no impact on SP. we will also see the short percentage later. I personally thought this two events will move us closer to $2. Apparently now we really need sk Hynix contract to see some movement in SP.
1 · Reply